INTRODUCTION
Significant advances in the treatment of metastatic melanoma have been made over the last decade, translating into meaningful survival benefit for patients. Therapeutic strategies may be broadly characterized into targeted therapy versus immunotherapy approaches-with several agents now approved by the US Food and Drug Administration (FDA) in each category. These agents are also being used to treat patients with earlier stage disease; however, resistance to therapy remains an issue across treatment types.
One of the most frequent mutations in melanoma involves the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene, with BRAF mutations present in approximately 50% of melanomas, leading to constitutive signaling of the mitogen-activated protein kinase (MAPK) pathway in affected cells. 1, 2 Pharmacologic targeting of this oncogenic mutation has been a qualified success, leading to the approval of several different BRAF inhibitors (vemurafenib in 2011, dabrafenib in 2013). 3, 4 However, despite a high response rate, the durability of responses has been limited (<6 months), and a deep query into resistance has ensued, uncovering numerous mechanisms of therapeutic resistance to BRAF-inhibitor monotherapy, many of which contribute to MAPK reactivation. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] On the basis of these findings, investigators developed combinatorial strategies incorporating mitogen-activated protein kinase kinase (MEK) inhibition and BRAF-inhibitor monotherapy with some success and a near doubling of progression-free survival. 15, 16 Therapeutic resistance remains an issue even with combined BRAF and MEK inhibition, and the majority of patients experience relapse of disease within 1 year of initiating therapy. [17] [18] [19] Nonetheless, durable responses may be observed in a subset of patients, and from 20% to 30% of patients remain progression free 4 years into therapy.
to the tumor, and prevention of trans-endocytosis of costimulatory molecules on antigen-presenting cells, thereby enhancing their capacity to prime T-cell responses. [22] [23] [24] Two large phase 3 clinical trials investigating treatment with ipilimumab in patients with metastatic melanoma demonstrated a survival benefit over then standard-ofcare chemotherapy, substantiating its FDA approval in 2011. 25, 26 Although overall objective response rates are modest (range, 10%-15%), treatment with CTLA-4 blockade is associated with long-term disease control in a subset of patients, with approximately 20% of treated patients achieving durable disease control (>10 years after initiating therapy). 25, 27 Other immune-checkpoint inhibitors were also developed during this time, including those targeting the programmed death-1 (PD-1) pathway and its ligands (PD-L1, PD-L2). PD-1 ligation leads to inactivation of T cells, although this mainly affects the effector phase of a T-cell response in peripheral tissues (such as in the tumor microenvironment). 28, 29 Treatment with monoclonal antibodies that block PD-1 is associated with response rates of approximately 40% in patients with metastatic melanoma, and 2 such agents were approved by the FDA in 2014 (pembrolizumab and nivolumab). 30, 31 It is noteworthy that treatment with these agents is associated with a lower incidence of toxicity compared with CTLA-4 blockade. 30, [32] [33] [34] [35] More recently, combination regimens with CTLA-4 and PD-1 blockade were tested in clinical trials and demonstrated a high response rate (>60%) and improvement in overall survival, although treatment with this regimen is also associated with a very high rate of toxicity. 36, 37 Additional forms of immunotherapy have been investigated and have demonstrated efficacy with the FDA approval of talimogene laherparepvec (TVEC) in 2015. TVEC is an oncolytic herpesvirus that was engineered to express human granulocyte-monocyte colonystimulating factor and is used as an intratumoral injection. 38 TVEC selectively replicates within tumor cells, causing tumor lysis and is also believed to elicit antitumor immune responses through enhanced antigen presentation by dendritic cells (DCs). [39] [40] [41] This agent was FDA approved for the treatment of unresectable stage IIIB, IIIC, and IV melanoma based on an improved durable response rate compared with granulocyte-monocyte colony-stimulating factor alone. 42 More recently, TVEC was tested in combination with immune-checkpoint inhibitors (ipilimumab and pembrolizumab) and demonstrated greater efficacy than expected with either drug alone; however, these agents were not compared in a randomized prospective design. 43, 44 Despite these advances, there are still significant proportions of patients who do not respond to therapy, and therapeutic decision making remains difficult based on different treatment choices and a paucity of reliable biomarkers for response. However, tremendous insights into molecular and immune mechanisms of response and resistance to these therapies have been gained and ultimately may help guide rational approaches to optimizing treatment.
INSIGHTS INTO THE EFFECTS OF MUTATIONS ON ANTITUMOR IMMUNITY
Over the past decade, we have made significant progress in understanding the effects of mutations on antitumor immunity. With the advent of next-generation sequencing and the use of targeted sequencing panels at the time of melanoma diagnosis, we now have more information on which to base therapeutic decisions, although the approach to date has been somewhat rudimentary.
Detailed genomic analyses of large melanoma cohorts have provided understanding of the key molecular features that contribute to the development of melanoma, including widespread dysregulation of the MAPK signaling pathway driven predominantly by BRAF and RAS (neuroblastoma rat sarcoma viral oncogene homolog [NRAS], Harvey rat sarcoma viral oncogene homolog [HRAS] , Kirsten rat sarcoma viral oncogene homolog [KRAS]) mutations. Additional significant alterations include phosphatase and tensin homolog (PTEN) inactivation either by mutation or deletion, and neurofibromatosis type 1 (NF-1) mutations. 45, 46 It is also known that cutaneous melanoma has the highest mutational burden among all cancers, likely related to damage by ultraviolet (UV) radiation. 47 Over the last decade, it has become apparent that the different molecular alterations can have distinct effects on the tumor microenvironment, which, in turn, influence the response to targeted therapies and immunotherapies. 48, 49 Thus, a deeper understanding of the immune effects of genomic mutations (and consequences of targeting these mutations) may facilitate the design of effective treatment strategies. Specific aspects of selected mutations and/or genomic alterations are discussed below. It is worth noting that several additional mutations may influence immune responses, but here we are highlighting the high-frequency mutations with strong evidence for an impact on antitumor immunity. Activating mutations in the BRAF gene (most commonly the valine-to-glutamic acid mutation at codon 600 [V600E]), lead to 10-fold greater kinase activity than that observed in normal cells, resulting in aberrant MAPK pathway activation, which protects melanocytes from apoptosis while driving tumorigenesis, invasiveness, and metastatic behavior. 50 It is noteworthy that this mutation also reportedly plays a role in immune evasion. [51] [52] [53] The first mechanistic report of the immunosuppressive effects of BRAF in melanoma came from Sumimoto et al in 2006 . 51 In their study, interleukin 6 (IL-6), IL-10, and vascular endothelial growth factor (VEGF) were identified and validated as immunosuppressive factors from the supernatant of cultured BRAF V600E melanoma cells, and these factors and their immunosuppressive function were reduced with pharmacologic MEK inhibition or BRAF V600E RNA interference treatment. 48, 51 At the same time, Kono et al demonstrated that BRAF V600E can suppress the expression of the melanoma antigens melanoma antigen recognized by T cells 1 (MART-1) and glycoprotein 100 (gp100), whereas MEK inhibition reverses this effect, also leading to increased recognition and killing by MART-1-specific cytotoxic T cells. 52 Khalili and colleagues also observed that BRAF V600E mutations caused immunosuppression by inducing IL-1 transcription in both melanocytes and melanoma cell lines, resulting in ) and phosphatase and tensin homolog (PTEN), b-catenin, and passenger mutations resulting in neoantigens on the immune tumor microenvironment are described. It has been established that the BRAF V600E mutation up-regulates the immunosuppressive cytokines vascular endothelial growth factor (VEGF), interleukin 1 (IL-1), IL-6, and IL-10 and down-regulates immunogenic melanoma antigens. It also has been demonstrated that PTEN loss increases the expression of VEGF, IL-6, IL-10, and C-C motif chemokine ligand 2 (CCL2), leading to reduced T-cell infiltration and poor response to checkpoint blockade. Aberrant b-catenin activity leads to increased expression of IL-10, reducing the ability of dendritic cells to mediate an antitumor T-cell response. Increases in mutational load and neoantigens result in a potential increase in the antigenicity of the tumor. MHC I indicates major histocompatibility complex class 1. enhanced ability of melanoma tumor-associated fibroblasts to suppress cytotoxic T-cell activity. 54 These in vitro findings are supported by preclinical models and translational work in human melanomas by several groups. 48, 49, [53] [54] [55] [56] [57] [58] Notably, longitudinal tissue immune profiling of patients undergoing selective BRAF inhibition with or without MEK inhibition demonstrated an increase in CD8-positive T-cell infiltrate within 2 weeks of initiation of treatment, an increase in the expression of melanoma antigens on tumor cells, an increase in markers of T-cell cytotoxicity, and a decrease in levels of immunosuppressive cytokines IL-6 and IL-8 ( Fig. 1) . 49, 59 It is noteworthy that immunomodulatory molecules PD-1 and PD-L1 were also increased with treatment. This is likely a mechanism of adaptive immune resistance, induced by tumor-infiltrating lymphocyte (TIL)-derived interferon gamma (IFN-c). However, it is important to note that, although PD-1/PD-L1 interaction is inhibitory, induction of these molecules as a result of BRAF therapy provides additional therapeutic targets in light of FDA approval of anti-PD-1 and anti-PD-L1 therapies, strengthening the rationale for combining targeted therapies with immune-checkpoint blockade.
Despite evidence for the immunosuppressive role of BRAF in vitro and in translational studies, meta-analyses of immunotherapy trials have not demonstrated a significant difference in response rates for patients with versus without a BRAF mutation. 60 This could have been because of insufficient power to detect a difference, or it may be related to the presence of other molecular and microenvironment factors affecting antitumor immunity. Nonetheless, it suggests that BRAF mutation status as a single variable is not sufficient to predict response to immunotherapy.
PTEN
Expression of the tumor suppressor PTEN is lost in up to 30% of melanomas, and loss of PTEN function is associated with aberrant activation of the phosphoinositide 3-kinase (PI3K) pathway, which can cooperate with mutant BRAF during tumorigenesis. 61, 62 In melanoma, PTEN loss is associated with both reduced T-cell infiltration and reduced T-cell function in vitro and in vivo, and 2 separate studies have outlined the mechanisms of immune suppression that occur with PTEN loss. 45, 63 Like in BRAF-mutant melanoma, IL-6, IL-10, and VEGF expression levels are key immunosuppressive features of PTEN inactivation, with PI3K signaling through signal transducer and activator of transcription 3 (STAT3) mediating the expression of these cytokines. 63 Furthermore, the immunosuppressant C-C motif chemokine ligand 2 (CCL2) is also overexpressed in PTEN-inactivated tumors. 45 It is encouraging to know that the effects of PTEN loss on both cytokine expression and T-cell infiltration and function are reversible with PI3K inhibitors, which increased the efficacy of anti-PD-1 therapy when administered in combination in a murine model. 45 These studies also demonstrated that PTEN loss is associated with reduced T-cell infiltration, reduced efficacy of ex vivo expansion of TILs, and poor response to anti-PD-1 checkpoint blockade in human studies (Fig. 1) . 63 This concept is now being translated to the clinic, and a trial is underway to test the safety and efficacy of combining a PI3K inhibitor with pembrolizumab in melanoma and other tumor types (clinicaltrials.gov identifier NCT02646748). One of the stated aims of this study is to investigate effects on the tumor microenvironment, which may help clarify the immune-related role of PI3K and the clinical feasibility of this combination. Notably, potential nuances exist with this type of approach, because studies have indicated that different isoforms of PI3K inhibitors have differential effects on T lymphocytes. 64 
NRAS
NRAS mutations are present in approximately 20% of melanomas, representing the second largest molecular subtype after BRAF-mutant melanoma. 65, 66 Activating mutations in NRAS, like BRAF, result in constitutive over-activation of the MAPK pathway. 67, 68 However, NRAS-mutant melanomas are also clinically distinct from BRAF-mutant melanomas, with a higher incidence in chronically sun-damaged skin, thicker lesions at presentation, and poorer prognosis. 69 The clinical response to immunotherapy is also different in the presence or absence of an NRAS mutation. Two independent studies have now observed a higher response rate to immunotherapy in NRAS-mutated melanomas. In an analysis of 208 patients with stage III/IV melanomas who received treatment with high-dose IL-2 (HD-IL-2), those who had NRAS mutations achieved significantly higher response rates compared with those who had BRAF-mutant or wild-type (WT) melanomas. 70 These findings were recently corroborated in a study that included HD-IL-2, ipilimumab, and anti-PD-L1/PD-1 therapies. Although increased response rates were observed in all immunotherapies, the benefits were most pronounced with the anti-PD-L1/PD-1 treatments. 71 The mechanism of these improved responses has not yet been fully elucidated. Joseph et al reported a correlation between serum lactate dehydrogenase levels and response to HD-IL-2, although how this is linked to an improved response to HD-IL-2 is unclear. 70 Elevated expression of PD-L1 in the NRAS cohort described by Johnson et al could explain these clinical differences, although their observations were in a small cohort and were not statistically significant. 71 The differential response to immunotherapies may also be explained in part by the specific immunosuppressive effects of BRAF mutation and PTEN loss in the other cohorts, especially because NRAS mutations are generally exclusive of both BRAF mutation and PTEN loss, which would clearly delineate these cohorts. 69 
Wnt/b-Catenin Signaling Pathway
Although mutations in the Wnt/b-catenin pathway occur at a relatively low rate in melanoma, it has been reported that dysregulation of this pathway is common, with 1 report of abnormal cytoplasmic/nuclear accumulation in one-third of melanomas. 72, 73 It is noteworthy that defects in the Wnt/b-catenin signaling pathway have been implicated in immunosuppression as an intrinsic mechanism within melanomas and also within local DCs. [74] [75] [76] Activation of b-catenin signaling directly increases expression of the immunosuppressive cytokine IL-10 in human melanoma, and this is linked to a reduced ability of DCs to stimulate a melanoma-specific, CD8-positive T-cell response. 77 Two studies have demonstrated that DCmediated inhibition of CD8-positive T-cell cross-priming itself is a process regulated by the Wnt/b-catenin pathway within the DCs. 75, 78 In addition, tumor-induced b-catenin activity in DCs can also induce regulatory T-cell differentiation. 76 Recent evidence also suggests that Wnt/bcatenin signaling in melanoma cells is linked to T-cell exclusion from the tumor microenvironment and that this is mediated by CCL4 transcription and a reduction in the recruitment of CD103-positive DCs. 74 When considering the potential clinical relevance of these findings, it is interesting to note that Wnt/b-catenin signaling-linked immunosuppressive effects can be reversed by pharmacologic targeting of the pathway. 76, 78 It may also be of therapeutic benefit that Wnt/b-catenin signaling can regulate immunosuppressive processes in different cell types through various mechanisms. Therefore, any targeting of this pathway may be broadly immunosensitizing, and this may improve efficacy and limit potential mechanisms of resistance (Fig. 1) .
Mutational Load/Neoantigens
Cutaneous melanoma is the most heavily mutated of all cancers because of induction of C-T transitions at dipyrimidine sites through exposure to UV irradiation. 47, 65, 79 Accumulation of these mutations often leads to alterations in the MAPK pathway in melanoma and in other melanoma driver genes, although UV exposure also leads to the generation of large numbers of other mutations that affect genes unrelated to proliferation or apoptosis and thus are unlikely to directly contribute to cancer progression. 65 However, recent work has brought to light the role that these "passenger mutations" may play in altering tumor immunogenicity. 79 Although high mutational load was once considered to be deleterious in cancer, it is now thought to have potentially beneficial immunogenic properties. 79, 80 The reasoning behind this is that a higher mutational load is generally associated with a higher level of neoantigens, which are defined as tumor-restricted antigens derived from mutations within transformed cells. 81 Considering the origin and randomness of their generation, neoantigens may be associated with increased tumor immunogenicity, because they are excluded from self-tolerance and deletion mechanisms at play during T-cell development. Increased mutational load and neoantigen burden therefore potentially allow for increased tumor immunogenicity through presentation of unique peptides more likely to be recognized by T cells (Fig. 1) .
Accordingly, neoantigen burden has been studied in the context of treatment with immune-checkpoint blockade as well as other forms of immunotherapy, such as adoptive T-cell therapy. 79, 80, 82 In the setting of treatment with CTLA-4 and PD-1 blockade, a higher mutational burden is correlated with favorable responses. 79, 80, 83 However, this is not specific to melanomas and has been observed in other cancer types, including non-small cell lung cancer as well as colorectal cancer, with high mismatch-repair mutations. 84 Although original reports relied on whole-exome sequencing to derive mutational load, algorithms have now been developed to calculate the "predicted total mutational load" from targeted sequencing panels of 200 genes. 85 In addition to these quantitative assessments, qualitative assessments of neoantigens have been used to develop personalized cancer therapies through the identification of neoantigens in tumors and validation of expression and reactivity against these antigens by autologous T cells. 82 Targeting of patientrestricted neoantigens has proven successful in this context, as demonstrated in a study by Tran and colleagues in which exome sequencing was performed, neoantigens were predicted based on patient human leukocyte antigen alleles, and infusion of mutated Erbb2 interacting protein In addition to interrogating known melanoma mutations for their influence on antitumor immunity, tremendous progress has been made in identifying resistanceconferring molecular alterations through the analysis of patient cohorts that received immunotherapy. Several high-impact studies have been done over the last several years, and the insights gained are informing strategies to overcome therapeutic resistance. In addition to the influence of mutational load, as described above, several other factors have been associated with response or resistance to immune-checkpoint blockade. 79 Genomic and transcriptomic characterization of a cohort treated with CTLA-4 blockade revealed that neoantigen burden and the expression of cytolytic markers also are associated with long-term clinical benefit. 83 Additional studies in the setting of CTLA-4 blockade have identified other mutations associated with improved survival, such as serpin peptidase inhibitor, clade B, member 3 (SERPINB3) and SERPINB4 mutations, which are hypothesized to enhance tumor immunogenicity. 86 Defects in IFN signaling may also serve as a mechanism of resistance to therapy, and studies have demonstrated that functional IFN-c is necessary for a successful immune response to CTLA-4 therapy. 87, 88 Several recent reports have also described molecular alterations associated with response and resistance to PD-1 blockade. Like CTLA-4 blockade, high mutational load is also associated with long-term clinical benefit. 89, 90 In addition, it has been demonstrated that responding tumors have a higher burden of mutations in breast cancer 2 (BRCA2), a DNA repair gene. 89 Therapeutic resistance is associated with defects in the antigen processing and presentation machinery (such as b2-microglobulin) and IFN-c signaling as well as up-regulation of genes involved in angiogenesis, extracellular matrix remodeling, cell adhesion, and mesenchymal transition. 88, 89 In addition, a recent study incorporating targeted sequencing revealed that patients with NF-1 mutations had high mutational load and high response rates to anti-PD-1, whereas patients who lacked BRAF/NRAS/NF-1 mutations had low mutational load. 90 One study to date has been published analyzing sequential treatment with CTLA-4 and PD-1 blockade that performed immune and geneexpression profiling in longitudinal tumor samples in the context of therapy. 91 In those studies, immune signatures in pretreatment samples were only modestly predictive of response to both CTLA-4 blockade as well as PD-1 blockade; however, the presence of a favorable immune signature in on-treatment tumor biopsies was highly predictive of response, particularly to anti-PD-1 therapy. More recently, genomic characterization of tumor samples has been performed in the same cohort, demonstrating copy number alterations as drivers of resistance to both forms of immune-checkpoint blockade. 92 
BUILDING ON INSIGHTS GAINED: COMBINING TARGETED THERAPY AND IMMUNOTHERAPY
With an understanding of the immune effects of oncogenic mutations and consequences of their therapeutic Abbreviations: 1 , with; 6 , with or without; BRAF, B-raf proto-oncogene serine/threonine kinase; BRAF V600, B-raf proto-oncogene serine/threonine kinase valine mutation at codon 600; CTLA-4, cytotoxic T-lymphocyte associated protein 4; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand; PEG-IFN, pegylated interferon; TIL, tumor-infiltrating lymphocytes; V600E/K, valine-to-glutamic acid or lysine substitution at codon 600. a Targeted targeting, coupled with a growing appreciation of molecular resistance mechanisms to immunotherapy-one may question if synergy will be seen when these agents are combined. Indeed this hypothesis has been posed, though early interest in combining targeted therapy and immunotherapy was largely clinically based-hoping to achieve high response rates (characterized by targeted therapy) and durable responses (characterized by immunotherapy). Since these trials were initiated, there is now also growing scientific rationale for combining these 2 treatment modalities, and a large number of trials exploring this strategy are currently underway (Table 1) . [93] [94] [95] [96] One of the first phase 1 clinical trials testing a BRAF inhibitor with immunotherapy involved the combination of BRAF inhibitor monotherapy (with vemurafenib) and a checkpoint inhibitor (targeting CTLA-4, ipilimumab).
Although responses were observed and there was evidence of synergy based on assessment of T-cell infiltrates within tumors from these patients, accrual to the trial was halted early, because grade 3 hepatotoxicity was observed in a significant proportion of these patients (6 of 12), highlighting the potential toxicity of these combinations. 93, 97 Another trial focused on the combination of BRAF and MEK inhibitors (dabrafenib and trametinib) with immune-checkpoint blockade targeting CTLA-4 (ipilimumab; clinicaltrials.gov identifier NCT107767454) in patients with stage IV, BRAF-mutant melanoma. In that trial, hepatotoxicity was still observed, although the magnitude was far less, suggesting that this may be drug specific rather than target specific. 95 Notably, the arm of the trial that incorporated treatment with the triplet combination was closed after several patients (2 of 7) developed colitis, with 1 patient requiring surgery. 98 This again highlights the unpredictability of toxicity profiles and the need for carefully designed and monitored, early phase clinical trials.
Compared with concurrent therapy, a phase 2 trial of sequential vemurafenib and ipilimumab demonstrated a more tolerable and manageable toxicity profile-65% of patients had grade 3 toxicities, the majority of which were skin toxicities-suggesting that combining these drugs in this manner may prove more beneficial. 96 Finally, given the improved tolerability of anti-PD-1/PD-L1 axis-targeting therapies compared with ipilimumab, trials are investigating combinations of these agents with targeted therapies. A recent report on a phase 1 trial of durvalumab/dabrafenib/trametinib for BRAF-mutant melanoma, durvalumab/trametinib for BRAF-WT melanoma, and sequential trametinib/durvalumab in BRAF-WT melanoma has also demonstrated a relatively more manageable toxicity profile, suggesting that combination with anti-PD-1/PDL-1 agents may be preferable. 99 Additional trials are underway exploring combinations of immunotherapy and targeted therapy (Table 1) , although mature data are not available. However, as results emerge, it is becoming increasingly clear that complexities exist with this approach; therefore, efforts must be made to use scientific evidence and iterative input from ongoing and completed trials to guide next-generation combination studies.
FURTHER REFINING COMBINATION STRATEGIES THROUGH BIOMARKER-DRIVEN CLINICAL TRIALS
Insights from preclinical models and translational research are paramount as we charter a path forward with rational combination strategies. This is important, because the numbers of patients required to test all possible Figure 3 . Translational studies provide an optimal approach to understanding mechanisms and accelerating patient benefit. Much success has come from approaches investigating longitudinal patient samples from clinical trials. These samples are then used to formulate hypotheses and develop appropriate animal models in which therapeutic mechanisms of response and resistance can be investigated and better understood to improve patient outcomes.
combinations of molecular-targeted and immunetargeted therapies using conventional clinical trial designs far exceed the numbers of available patients for such studies. Thus it may be necessary to move to more novel, biomarker-heavy clinical trial designs in an effort to incorporate insights gained from genomic and immune analyses (Fig. 2) .
From a trial standpoint, adaptive trial design provides 1 possible means of more efficiently assessing combination therapies. 100 In this design, Bayesian modeling may be used to combine a priori hypotheses and estimation of variables along with data collected from the ongoing trial regarding efficacy and toxicity. On the basis of an adjusted set of parameters at prespecified interim analyses, the trial design can be modified regarding dose escalation, sample size, population or subpopulations studied, treatment allocation, randomization probabilities, and study endpoint (for example, changing from superiority to noninferiority endpoint), among other variables. 100 An example in melanoma in which an adaptive trial design was used is the LOGIC 2 trial, which was designed to combine initial treatment with BRAF and MEK inhibitors, binimetinib and encorafenib, until the time of progression, at which point patients received 1 of several different treatments based on the molecular profile of their biopsy at the time of progression. The trial also incorporated Bayesian modeling based on accumulating toxicity data to minimize the number of patients on doses with excessive toxicity and maximized exposure to doses that were both tolerable and efficacious. Such a flexible design approach allows for more efficient testing of combinations that can ascertain efficacy, minimize toxicity, and use data from biomarker analysis.
Furthermore, it is prudent to take findings gained from translational research studies back to appropriate preclinical models, with validation and optimization of different combination strategies, before returning these insights to patients (Fig. 3 ). An example of this type of an approach was recently published, describing the immunosuppressive effects of PTEN loss and responses to immunotherapy. 45 In those studies, tumor samples from patients with melanoma were interrogated and noted to have exclusion of CD8-positive T cells in regions of PTEN loss within tumors. The impact of this on response to anti-PD-1 therapy was assessed, and an association was demonstrated between PTEN loss in tumors from patients with lack of response to PD-1-based therapy. 45 These findings were then translated to a murine model and indicated that treatment of mice with combined PI3K pathway inhibitors and PD-1 checkpoint blockade was associated with delayed tumor outgrowth and enhanced survival. This research is now being translated again back to patients in the form of clinical trials combining PI3K inhibitors with immune-checkpoint inhibitors (clinicaltrials.gov identifier NCT02646748).
CHALLENGES
Despite the successes and insights gained from these studies, major obstacles inherently remain. First, although several molecular features, such as total mutational load, the burden of copy number losses, and others described in this review, are associated with responses to immunotherapy, there is significant overlap between responders and nonresponders with regard to each of these variables; therefore, each on its own is not a reliable biomarker. Recent studies suggest that an integrated analysis of several of these variables may prove more useful in predicting responses, although this needs to be validated in larger cohorts and across cancer types. 92 In addition, recent studies suggest that early ontreatment biopsies may be far superior to baseline biopsies in predicting therapeutic response; however, tumors are not always readily accessible for sampling, and limitations in the amount of tissue obtained with biopsies may limit the analyses that may be performed. 45, 101 In addition, despite their better predictive ability, these on-treatment signatures require treatment of patients with 1 or 2 cycles of their therapies, which is not ideal in the long term and highlights the need to identify pretreatment biomarkers of response to therapy. Although it is currently limited, the identification of biomarkers within liquid biopsies may hold the most promise in the least invasive manner and make on-treatment biopsies more pragmatic. "Liquidbiopsy" approaches are in development for melanoma and other cancers; however, large studies will be needed to validate their prognostic and predictive role. 102, 103 SUMMARY AND CONCLUSIONS Targeted therapy and immunotherapy represent major advances in the treatment of melanoma, offering a real and tangible opportunity to help achieve long-term disease control. However, resistance mechanisms to these therapies, either alone or in combination, continue to emerge. A more comprehensive understanding of molecular alterations in melanoma and of the molecular mechanisms that contribute to immune evasion will allow us to design better and more effective treatment strategies in this age of personalized cancer therapy.
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